Revenue grew 2.6% year-over-year to €3.57 billion, with net profit up 28.7% and adjusted EBITDA at €854 million. Biopharma led growth, especially in immunoglobulins, while Diagnostics repositioned for future expansion. Strong liquidity and successful refinancing support the 2026 outlook.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.